(Q35616224)
Statements
Cancer immunotherapy targeting survivin: commentary re: V. Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res., 9:6523-6533, 2003 (English)
John C Reed
Darcy B Wilson
1 December 2003